SCHEDULE: Morgan Stanley Discloses 6.7% Stake in C4 Therapeutics

Morgan Stanley has disclosed a 6.7% beneficial ownership stake in C4 Therapeutics, Inc. common stock.

Summary

• Morgan Stanley, a Delaware-based entity, has reported beneficial ownership of 4,750,383 shares of C4 Therapeutics, Inc. Common Stock.
• This ownership represents 6.7% of the class of securities.
• Morgan Stanley holds shared voting power over 4,749,421 shares and shared dispositive power over 4,750,383 shares.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating an update to a previously reported stake.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of C4 Therapeutics, Inc.

Sentiment

Score: 5

Explanation: The filing is a neutral, factual disclosure of beneficial ownership by an institutional investor, with no explicit positive or negative operational implications for the issuer.

Future Outlook

NA

Industry Context

This filing is a standard disclosure by a large financial institution, Morgan Stanley, regarding its passive investment stake in a publicly traded biotechnology company, C4 Therapeutics. It reflects routine portfolio management and compliance with SEC reporting requirements for significant beneficial ownership.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, confirming a passive investment approach.

Key Dates

Keywords

C4 Therapeutics, Morgan Stanley, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investment, SEC Filing